Institution
Autonomous University of Barcelona
Education•Cerdanyola del Vallès, Spain•
About: Autonomous University of Barcelona is a education organization based out in Cerdanyola del Vallès, Spain. It is known for research contribution in the topics: Population & Context (language use). The organization has 37833 authors who have published 80514 publications receiving 2321142 citations. The organization is also known as: Universitat Autònoma de Barcelona & Computer Vision Center.
Topics: Population, Context (language use), Medicine, Cancer, Transplantation
Papers published on a yearly basis
Papers
More filters
••
TL;DR: In this paper, the authors developed a simple description of models where electroweak symmetry breaking is triggered by a light composite Higgs, which emerges from a strongly-interacting sector as a pseudo-Goldstone boson.
Abstract: We develop a simple description of models where electroweak symmetry breaking is triggered by a light composite Higgs, which emerges from a strongly-interacting sector as a pseudo-Goldstone boson. Two parameters broadly characterize these models: mρ, the mass scale of the new resonances and gρ, their coupling. An effective low-energy Lagrangian approach proves to be useful for LHC and ILC phenomenology below the scale mρ. We identify two classes of operators: those that are genuinely sensitive to the new strong force and those that are sensitive to the spectrum of the resonances only. Phenomenological prospects for the LHC and the ILC include the study of high-energy longitudinal vector boson scattering, strong double-Higgs production and anomalous Higgs couplings. We finally discuss the possibility that the top quark could also be a composite object of the strong sector.
1,015 citations
••
TL;DR: This first multicentre study assessing the long-term efficacy of either STN or GPi stimulation shows a significant and substantial clinically important therapeutic benefit for at least 3-4 years in a large cohort of patients with severe Parkinson's disease.
Abstract: Deep brain stimulation (DBS) is associated with significant improvement of motor complications in patients with severe Parkinson's disease after some 6-12 months of treatment. Long-term results in a large number of patients have been reported only from a single study centre. We report 69 Parkinson's disease patients treated with bilateral DBS of the subthalamic nucleus (STN, n = 49) or globus pallidus internus (GPi, n = 20) included in a multicentre study. Patients were assessed preoperatively and at 1 year and 3-4 years after surgery. The primary outcome measure was the change in the 'off' medication score of the Unified Parkinson's Disease Rating Scale motor part (UPDRS-III) at 3-4 years. Stimulation of the STN or GPi induced a significant improvement (50 and 39%; P < 0.0001) of the 'off' medication UPDRS-III score at 3-4 years with respect to baseline. Stimulation improved cardinal features and activities of daily living (ADL) (P < 0.0001 and P < 0.02 for STN and GPi, respectively) and prolonged the 'on' time spent with good mobility without dyskinesias (P < 0.00001). Daily dosage of levodopa was significantly reduced (35%) in the STN-treated group only (P < 0.001). Comparison of the improvement induced by stimulation at 1 year with 3-4 years showed a significant worsening in the 'on' medication motor states of the UPDRS-III, ADL and gait in both STN and GPi groups, and speech and postural stability in the STN-treated group. Adverse events (AEs) included cognitive decline, speech difficulty, instability, gait disorders and depression. These were more common in patients treated with DBS of the STN. No patient abandoned treatment as a result of these side effects. This experience, which represents the first multicentre study assessing the long-term efficacy of either STN or GPi stimulation, shows a significant and substantial clinically important therapeutic benefit for at least 3-4 years in a large cohort of patients with severe Parkinson's disease.
1,013 citations
••
Marcos Daniel Actis1, G. Agnetta2, Felix Aharonian3, A. G. Akhperjanian +682 more•Institutions (109)
TL;DR: The ground-based gamma-ray astronomy has had a major breakthrough with the impressive results obtained using systems of imaging atmospheric Cherenkov telescopes as mentioned in this paper, which is an international initiative to build the next generation instrument, with a factor of 5-10 improvement in sensitivity in the 100 GeV-10 TeV range and the extension to energies well below 100GeV and above 100 TeV.
Abstract: Ground-based gamma-ray astronomy has had a major breakthrough with the impressive results obtained using systems of imaging atmospheric Cherenkov telescopes. Ground-based gamma-ray astronomy has a huge potential in astrophysics, particle physics and cosmology. CTA is an international initiative to build the next generation instrument, with a factor of 5-10 improvement in sensitivity in the 100 GeV-10 TeV range and the extension to energies well below 100 GeV and above 100 TeV. CTA will consist of two arrays (one in the north, one in the south) for full sky coverage and will be operated as open observatory. The design of CTA is based on currently available technology. This document reports on the status and presents the major design concepts of CTA.
1,006 citations
••
Mayo Clinic1, University of Pittsburgh2, Autonomous University of Barcelona3, University of Alberta4, Karolinska University Hospital5, University of Florida6, New York Methodist Hospital7, United States Department of Veterans Affairs8, George Washington University9, University of Duisburg-Essen10, Albert Einstein College of Medicine11, Virginia Commonwealth University12, Otto-von-Guericke University Magdeburg13, Vrije Universiteit Brussel14, Ghent University Hospital15, Hospital of the University of Pennsylvania16, University of Chicago17, Duke University18, University of Maryland, Baltimore19, RWTH Aachen University20, St. John Providence Health System21, University of California, San Diego22, St Thomas' Hospital23, Beth Israel Deaconess Medical Center24, Medical University of Vienna25, Tampa General Hospital26, Goethe University Frankfurt27
TL;DR: Two novel markers for AKI have been identified and validated in independent multicenter cohorts and are superior to existing markers, provide additional information over clinical variables and add mechanistic insight into AKI.
Abstract: Introduction: Acute kidney injury (AKI) can evolve quickly and clinical measures of function often fail to detect AKI at a time when interventions are likely to provide benefit. Identifying early markers of kidney damage has been difficult due to the complex nature of human AKI, in which multiple etiologies exist. The objective of this study was to identify and validate novel biomarkers of AKI. Methods: We performed two multicenter observational studies in critically ill patients at risk for AKI - discovery and validation. The top two markers from discovery were validated in a second study (Sapphire) and compared to a number of previously described biomarkers. In the discovery phase, we enrolled 522 adults in three distinct cohorts including patients with sepsis, shock, major surgery, and trauma and examined over 300 markers. In the Sapphire validation study, we enrolled 744 adult subjects with critical illness and without evidence of AKI at enrollment; the final analysis cohort was a heterogeneous sample of 728 critically ill patients. The primary endpoint was moderate to severe AKI (KDIGO stage 2 to 3) within 12 hours of sample collection. Results: Moderate to severe AKI occurred in 14% of Sapphire subjects. The two top biomarkers from discovery were validated. Urine insulin-like growth factor-binding protein 7 (IGFBP7) and tissue inhibitor of metalloproteinases-2 (TIMP-2), both inducers of G1 cell cycle arrest, a key mechanism implicated in AKI, together demonstrated an AUC of 0.80 (0.76 and 0.79 alone). Urine [TIMP-2]·[IGFBP7] was significantly superior to all previously described markers of AKI (P 0.72. Furthermore, [TIMP2]·[IGFBP7] significantly improved risk stratification when added to a nine-variable clinical model when analyzed using Cox proportional hazards model, generalized estimating equation, integrated discrimination improvement or net reclassification improvement. Finally, in sensitivity analyses [TIMP-2]·[IGFBP7] remained significant and superior to all other markers regardless of changes in reference creatinine method.
997 citations
••
Vita-Salute San Raffaele University1, Uppsala University2, National and Kapodistrian University of Athens3, University of Marburg4, Autonomous University of Barcelona5, University College London6, Medical University of Silesia7, Erasmus University Rotterdam8, Technische Universität München9, Gartnavel General Hospital10, National Institutes of Health11
TL;DR: The ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatics with Functional and non-functional tumours is published.
Abstract: Only advances that occurred from 2011–2014 that either strengthen the previous 2011 guidelines [1;2] or lead to changes or additional guidelines are reviewed here. Advances and modifications in the treatment of advanced metastatic disease is only briefly dealt with here as it is covered in a separate chapter, similar to the 2011 guideline format [3]. The format used here is the same as used in the 2011 guidelines with page references to the appropriate section inserted [1;2] and this document is meant as a supplement to these guidelines and does not reiterate all of the points made in the previous guidelines, only changes, supporting findings or modifications of the 2011 guidelines are thus covered here.
As in the previous F-p-NET guidelines [1], the F-p-NETs will be considered in three groups: the more frequent gastrinomas and insulinomas considered independently and all the rare functional p-NETs (RFTs) considered together and as a separate category (Annex 1 and Table 1).
Table 1
Functional Pancreatic endocrine tumors [F-p-NET] syndromes
988 citations
Authors
Showing all 38202 results
Name | H-index | Papers | Citations |
---|---|---|---|
Adrian L. Harris | 170 | 1084 | 120365 |
Yang Gao | 168 | 2047 | 146301 |
Alvaro Pascual-Leone | 165 | 969 | 98251 |
David R. Jacobs | 165 | 1262 | 113892 |
Donald G. Truhlar | 165 | 1518 | 157965 |
J. S. Lange | 160 | 2083 | 145919 |
Joseph Wang | 158 | 1282 | 98799 |
José Baselga | 156 | 707 | 122498 |
Stephen J. Chanock | 154 | 1220 | 119390 |
Michael A. Matthay | 151 | 998 | 98687 |
David D'Enterria | 150 | 1592 | 116210 |
G. Eigen | 148 | 2188 | 117450 |
Inkyu Park | 144 | 1767 | 109433 |
Teruki Kamon | 142 | 2034 | 115633 |
Detlef Weigel | 142 | 516 | 84670 |